The latest medical news on Myeloma

A combination therapy with Darzalex Faspro would treat adults newly diagnosed with multiple myeloma and eligibile for a stem cell transplant.

The FDA has approved an every-other-week dosing regimen of Tecvayli for myeloma patients who have responded well to weekly dosing.

The international Myeloima Action Month campaign is designed to improve awareness of myeloma among policymakers, researchers, and others.

Health Canada approved Elrexfio as a myeloma treatment for patients with recurring or hard-to-treat cancer, conditioned on further studies.

Blenrep reduced the risk of disease progression or death by more than half in relapsed or refractory multiple myeloma over Darzalex.

A European regulatory advisory committee has issued a positive opinion on the use of Abecma in earlier lines of treatment for myeloma.

A dysregulated immune response against viruses that cause hepatitis may cause some cases of myeloma, requiring treatment, a study suggests.

Obesity and other lifestyle factors were seen to raise a risk of MGUS, a precursor condition to multiple myeloma, in a large study.

STAR-LLD, a continuous infusion of low-dose lenalidomide, plus Velcade and dexamethasone are showing safety, early efficacy in Phase 1b study.

AstraZeneca is set to buy Gracell in a deal that will add the biotech's experimental dual-targeting CAR T-cell therapy GC012F to its pipeline.

Darzalex Faspro plus standard therapy significantly improved outcomes with transplant-eligible, newly diagnosed multiple myeloma.

The European Commission gave conditional approval to Elrexfio for adults with RRMM and cancer worsening after last of three lines of therapy.